Hallucinations	hallucinations	O	S_disease
and	and	O	O
ifosfamide-induced	ifosfamide-induced	O	O
neurotoxicity	neurotoxicity	O	S_disease
.	.	O	O

BACKGROUND	background	O	O
:	:	O	O
Hallucinations	hallucinations	O	S_disease
as	as	O	O
a	a	O	O
symptom	symptom	O	O
of	of	O	O
central	central	O	O
neurotoxicity	neurotoxicity	O	S_disease
are	are	O	O
a	a	O	O
known	known	O	O
but	but	O	O
poorly	poorly	O	O
described	described	O	O
side	side	O	B_disease
effect	effect	O	I_disease
of	of	O	O
ifosfamide	ifosfamide	S_chemicals	O
.	.	O	O

Most	most	O	O
cases	cases	O	O
of	of	O	O
ifosfamide-induced	ifosfamide-induced	O	O
hallucinations	hallucinations	O	S_disease
have	have	O	O
been	been	O	O
reported	reported	O	O
with	with	O	O
other	other	O	O
mental	mental	O	O
status	status	O	O
changes	changes	O	O
.	.	O	O

METHODS	methods	O	O
:	:	O	O
The	the	O	O
authors	authors	O	O
interviewed	interviewed	O	O
six	six	O	O
persons	persons	O	O
with	with	O	O
ifosfamide-induced	ifosfamide-induced	O	O
hallucinations	hallucinations	O	S_disease
in	in	O	O
the	the	O	O
presence	presence	O	O
of	of	O	O
a	a	O	O
clear	clear	O	O
sensorium	sensorium	O	O
.	.	O	O

All	all	O	O
patients	patients	O	O
were	were	O	O
receiving	receiving	O	O
high-dose	high-dose	O	O
ifosfamide	ifosfamide	S_chemicals	O
as	as	O	O
part	part	O	O
of	of	O	O
their	their	O	O
bone	bone	O	B_disease
marrow	marrow	O	I_disease
transplant	transplant	O	O
procedure	procedure	O	O
.	.	O	O

RESULTS	results	O	O
:	:	O	O
Hallucinations	hallucinations	O	S_disease
occurred	occurred	O	O
only	only	O	O
when	when	O	O
the	the	O	O
patient	patient	O	O
's	's	O	O
eyes	eyes	O	O
were	were	O	O
closed	closed	O	O
and	and	O	O
,	,	O	O
in	in	O	O
all	all	O	O
but	but	O	O
one	one	O	O
case	case	O	O
,	,	O	O
were	were	O	O
reported	reported	O	O
as	as	O	O
disturbing	disturbing	O	O
or	or	O	O
frightening	frightening	O	O
.	.	O	O

Underreporting	underreporting	O	O
of	of	O	O
these	these	O	O
hallucinations	hallucinations	O	S_disease
by	by	O	O
patients	patients	O	O
is	is	O	O
likely	likely	O	O
.	.	O	O

CONCLUSIONS	conclusions	O	O
:	:	O	O
Hallucinations	hallucinations	O	S_disease
may	may	O	O
be	be	O	O
the	the	O	O
sole	sole	O	O
or	or	O	O
first	first	O	O
manifestation	manifestation	O	O
of	of	O	O
neurotoxicity	neurotoxicity	O	S_disease
.	.	O	O

The	the	O	O
incidence	incidence	O	O
may	may	O	O
be	be	O	O
dose	dose	O	O
and	and	O	O
infusion-time	infusion-time	O	O
related	related	O	O
.	.	O	O

The	the	O	O
clinician	clinician	O	O
should	should	O	O
be	be	O	O
alerted	alerted	O	O
for	for	O	O
possible	possible	O	O
ifosfamide-induced	ifosfamide-induced	O	O
hallucinations	hallucinations	O	S_disease
,	,	O	O
which	which	O	O
may	may	O	O
occur	occur	O	O
without	without	O	O
other	other	O	O
signs	signs	O	O
of	of	O	O
neurotoxicity	neurotoxicity	O	S_disease
.	.	O	O
"	"	O	O
Eyes-closed	eyes-closed	O	O
"	"	O	O
hallucinatory	hallucinatory	O	O
experiences	experiences	O	O
appear	appear	O	O
to	to	O	O
be	be	O	O
an	an	O	O
unusual	unusual	O	O
feature	feature	O	O
of	of	O	O
this	this	O	O
presentation	presentation	O	O
.	.	O	O

Patients	patients	O	O
anxious	anxious	O	O
about	about	O	O
this	this	O	O
experience	experience	O	O
respond	respond	O	O
well	well	O	O
to	to	O	O
support	support	O	O
and	and	O	O
education	education	O	O
about	about	O	O
this	this	O	O
occurrence	occurrence	O	O
.	.	O	O

Optimal	optimal	O	O
pharmacologic	pharmacologic	O	O
management	management	O	O
of	of	O	O
disturbed	disturbed	O	O
patients	patients	O	O
is	is	O	O
unclear	unclear	O	O
.	.	O	O

If	if	O	O
agitation	agitation	O	O
becomes	becomes	O	O
marked	marked	O	O
,	,	O	O
high-potency	high-potency	O	O
neuroleptics	neuroleptics	S_chemicals	O
(	(	O	O
i.e.	i.e.	O	O
,	,	O	O
haloperidol	haloperidol	O	O
)	)	O	O
may	may	O	O
be	be	O	O
effective	effective	O	O
.	.	O	O

